CALCULATE YOUR SIP RETURNS

Stocks To Watch Today on October 11, 2024: TCS, Tata Elxsi, Ola Electric Shares in Focus

11 October 20243 mins read by Angel One
Check out the stocks to watch on October 11, 2024, as the latest announcements made by the companies may lead to movement in their share prices
Stocks To Watch Today on October 11, 2024: TCS, Tata Elxsi, Ola Electric Shares in Focus
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

On October 11 at 08:12 AM, the SGX Nifty was trading lower by 0.08% to 25,089.5, indicating a muted opening of the Indian benchmark indices Nifty 50 and Sensex.  Check out a few stocks, which will be in focus during the trading session.

  • Tata Consultancy Services Ltd

In Q2 FY25, TCS reported a net profit of Rs 11,909 crore, reflecting a 5% increase year-on-year but a 1.08% decline sequentially. Revenue rose by 7.6% to Rs 64,259 crore.

  • Tata Elxsi:

The engineering and technology firm achieved a 14.7% year-on-year profit increase, reaching Rs 229 crore, driven by strong demand in its transportation sector. 

  • Ola Electric

The company is currently under investigation by the Ministry of Heavy Industries due to consumer complaints regarding delayed deliveries and product defects. Ola Electric is cooperating with an inquiry by the Automotive Research Association of India (ARAI) and aims to clarify compliance timelines..

  • One97 Communications:

Paytm’s share price has recently risen following the successful migration of its payment handle and the receipt of foreign direct investment clearance for its Payment Aggregator license. With a stable market share in UPI and plans to expand into other financial services, the company aims for a positive Adjusted EBITDA by Q4 FY25.

  • JSW Steel

The company has teamed up with BHP and Carbon Clean to enhance carbon capture technology in steel production. This initiative is designed to lower emissions and aligns with the company’s commitment to global sustainability efforts.

  • Zydus Lifesciences:s

The company has received approval from the US FDA to manufacture its generic version of Paliperidone extended-release tablets for the treatment of schizophrenia.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Enjoy ₹0 Account Opening Charges

Join our 2 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Send App Link
Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Enjoy ₹0 Account Opening Charges